Neil Strotman is a Director, Oral Formulations Science at Merck, whose known portfolio counts 27 companies.
Is Neil Strotman a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- AIHealthcare
Contacts
Affiliated funds' portfolios
Director, Oral Formulations Science at Merck, whose known portfolio counts 27 companies
- Mosaic
- Octave
- Artios Pharma
- Unnatural Products
- Formo
- Ambrosia Biosciences
- Atropos Health
- PreciseDx
- Moderna
- Aktis Oncology
- Orna Therapeutics
- Variational AI
- and 15 more
Investor Profile
Founders in the listed sectors AI and Healthcare, and focus areas AI Applications, Biotech, Diagnostics and Drug Discovery fall inside that listing.
Merck appears in Growth, Late-Stage and Seed rounds across its known deals.
What the affiliated firm has backed is the closest available signal on whether Neil Strotman is worth approaching.
Colleagues at Merck
Joe Volpe
Managing Director
Hatfield, United States
Olga Danilchanka
Partner, MRL Ventures Fund
Cambridge, United States
Peter Dudek
President & Managing Partner, MRL Ventures Fund
Cambridge, United States
Tao Fang
Investor
Boston, United States
Harry Arader
President
St Louis, United States
William Taranto
President
New Hope, United States
Tony Martinez
Investor
Lambertville, United States
Sammie Irwin
Investor
O'Fallon, United States
Pan Fsa
Venture Capital & Private Equity Professional
India
Frequently asked questions
Who is Neil Strotman?
Neil Strotman is a corporate venture investor based in Metuchen, New Jersey, United States, listed as Director, Oral Formulations Science at Merck. The known portfolio of that firm counts 27 companies. That portfolio belongs to the firm, not to Neil Strotman personally.
What does Neil Strotman invest in?
Listed sectors include AI and Healthcare; listed focus areas include AI Applications, Biotech, Diagnostics and Drug Discovery. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Neil Strotman invest at?
Merck appears in Growth, Late-Stage and Seed rounds across its known deals, and Neil Strotman is listed there as Director, Oral Formulations Science. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Neil Strotman listed at?
Neil Strotman is listed as Director, Oral Formulations Science at Merck. 9 other people in the database share a firm with Neil Strotman.
How do I contact Neil Strotman?
An email address, a phone number and a LinkedIn page are on file for Neil Strotman. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal